Search 

Intract Pharma Limited is an oral drug delivery licensing and product development company offering a range of proprietary formulation technologies to deliver novel and optimised therapeutics targeted to patient needs. The company is a spin-out of University College London, and is centred around over 15 years of research and innovation from the laboratory of Professor Abdul Basit. Intract's range of formulation technologies includes Phloral™ for colon targeted delivery, and ProRelease™, a versatile microparticulate delivery system.

Isogenica is at the forefront of synthetic biology, pursuing a mission to provide the fastest, most efficient engine for therapeutic antibody discovery. Isogenica is developing LlamdA™ (single domain VHH) and Alexandria™ (human Fab) therapeutic antibodies based on its proprietary fully synthetic antibody libraries and leveraging its CIS Display and Colibra™ technologies to accelerate the discovery and development process.

Karma Oncology is a specialised oncology clinical development company headquartered in Scotland with offices in Netherlands and USA.  We offer a complete range of development services from clinical development planning, protocol design and authoring, strategic country/site selection, regulatory submissions, through to clinical trial execution and reporting. 

Adaptable - We can provide selected individual services, and extend to full-service global CRO capabilities clients require.  Our size allows us to be flexible, innovative and responsive to individual sponsor requirements and to adhere strictly to sponsor specified development timelines.

Reliable - Our Project Managers have extensive oncology experience, our monitors are professional, mature 'career' CRAs - not trainees - and we have the lowest staff turnover in the industry (<5%).  Many of our staff come from a nursing or medical background, and for international studies we use CRAs native to their country.

Motivated - Our team has successfully completed programs in a broad range of solid tumour and hematologic indications utilising an array of different therapeutic approaches including immunotherapy and cell therapies (autologous, CAR-T and CAR-NK).

Accountable – The Karma team focus on delivering quality while respecting sponsor timelines (not internal timelines) and will do what it takes to do so.

Lifescience Industry magazine is a collaboration between regional, national and international life science partners including BioPartner UK.

It includes the latest news and developments from the life science industry, with editorial covering the complete health technology spectrum, as well as funding, trade and collaboration opportunities. 
Currently circulated twice a year to over 40,000 named individuals, it is consistently distributed at key industry events around the world and is available online.

BioPartner members can submit articles free of charge, and receive 15% off all advertising packages.

LSX is a growing influential community of senior life science decision makers, and are a catalyst for dialogue, debate and deal making to help lead growth in healthcare investment and the building of billion pound healthcare businesses. LSX is determined to forge a fundamentally better way to promote and facilitate investment, financing, partnerships and deal making in healthcare.

Their community helps catalyse early stage innovation through peer-to-peer education and knowledge sharing, networking, partnering and deal making to champion the most innovative and exciting ideas. LSX brings deals to life.

Mawdsleys is the largest independent pharmaceutical wholesalers in the UK with a fast-growing international network supplying medicines to meet patient needs and providing a route to market for manufacturers.

With a history tracing back to 1825, Mawdsleys has the pedigree and resources to be the reliable and experienced supplier of choice to hospitals and pharmacies around the world.

MedCity is the life sciences cluster organisation for London and the greater south east of England, set up in 2014 by the Mayor of London and the region’s three Academic Health Science Centres. They are funded by the Greater London Authority and Research England, and as a not-for-profit are able to act as a neutral and independent convener across industry, academia and the public sector.

London and the greater south east is home to a rich life sciences cluster, with more than 3,400 life sciences companies, four of the world’s top ten universities, 19 of the top 20 global pharmaceutical companies and world class research centres including The Francis Crick Institute, Harwell Oxford and The Sanger Institute.

MedCity's ambition is for their region to be the unequivocal place of choice for world-leading health and life sciences innovation, R&D, manufacture and commercialisation.

Medherant is developing a pipeline of products for pain and neurology indications, based on our next-generation TEPI-Patch® transdermal drug technology. Our first product – Ibuprofen TEPI Patch – entered the clinic in 2018.

Key advantages of the TEPI Patch® technology over current technologies are the high payload and very efficient release of drug.  This enables lower potency drugs to be formulated as a patch and provides the opportunity to increase the dose of drugs already administered via a patch whilst also minimising the residual drug after use.  

The TEPI Patch® also provides a better experience for the user as it does not leave a residue around the patch – referred to as ‘cold flow’ – and has excellent adhesion whilst still being easy and painless to remove. No organic solvents are involved in this drug-in-adhesive system.

As well as developing our own products, Medherant offers pharma companies rapid feasibility studies using our proprietary high throughput permeation study system to develop transdermal formulations of their drugs of interest.

MediWales is the life science network and representative body for Wales.
An independent, not-for-profit organisation that is owned by its members, MediWales provides advice, support, business opportunities and promotes collaborations for the life science and health technology community in Wales.

MediWales delivers an extensive events programme, including the UK HealthTech conference and the MediWales Innovation Awards and produces a number of publications including UK Lifescience Industry magazine, the Annual Directory and Review, and case study magazine LifeStories. MediWales promotes and supports its members in Wales, across the UK and internationally. 

Mironid is an innovative drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signaling proteins.